Pathogenesis of pulmonary fibrosis in systemic sclerosis: Lessons from interstitial lung disease

Current Rheumatology Reports

Volumn 12, Issue 1, 2010, Pages 19-25

  Veraldi, Kristen L ^a   Hsu, Eileen ^a   Feghali Bostwick, Carol A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis; Interstitial lung disease; Scleroderma

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CYTOKINE; GROWTH FACTOR; LUNG SURFACTANT; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY DETECTION; DISEASE COURSE; EPIGENETICS; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEREDITY; HIGH RISK PATIENT; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG FIBROSIS; LUNG LAVAGE; MUTATIONAL ANALYSIS; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TELOMERE;

EPIGENESIS, GENETIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 77249172574     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0071-8     Document Type: Review

References (50)

1. VD Steen TA Medsger 2000 Severe organ involvement in systemic sclerosis with diffuse scleroderma Arthritis Rheum 43 2437 2444 10.1002/1529-0131(200011) 43:11<2437::AID-ANR10>3.0.CO;2-U 1:STN:280:DC%2BD3M%2FktFequw%3D%3D 11083266 (Pubitemid 30829267)
2. VD Steen TA Medsger 2007 Changes in causes of death in systemic sclerosis, 1972-2002 Ann Rheum Dis 66 940 944 10.1136/ard.2006.066068 17329309 (Pubitemid 46999798)
3. A Fischer RT Meehan CA Feghali-Bostwick, et al. 2006 Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease Chest 130 976 981 10.1378/chest.130.4.976 17035427 (Pubitemid 44583724)
4. B White 2003 Interstitial lung disease in scleroderma Rheum Dis Clin North Am 29 371 390 10.1016/S0889-857X(03)00025-5 12841300
5. D Bouros AU Wells AG Nicholson, et al. 2002 Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome Am J Respir Crit Care Med 165 1581 1586 10.1164/rccm.2106012 12070056 (Pubitemid 34693935)
6. DS Kim B Yoo JS Lee, et al. 2002 The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia Sarcoidosis Vasc Diffuse Lung Dis 19 121 127 12108451
7. KR Flaherty WD Travis TV Colby, et al. 2001 Histopathologic variability in usual and nonspecific interstitial pneumonias Am J Respir Crit Care Med 164 1722 1727 1:STN:280:DC%2BD38zgsVeqtA%3D%3D 11719316
8. JA Bjoraker JH Ryu MK Edwin, et al. 1998 Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 157 199 203 1:STN:280:DyaK1c7gs1Skug%3D%3D 9445300
9. ZD Daniil FC Gilchrist AG Nicholson, et al. 1999 A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis Am J Respir Crit Care Med 160 899 905 1:STN:280:DyaK1Mvgtlagtg%3D%3D 10471616
10. KR Flaherty JA Mumford S Murray, et al. 2003 Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia Am J Respir Crit Care Med 168 543 548 10.1164/rccm.200209-1112OC 12773329 (Pubitemid 37088596)
11. Y Jegal DS Kim TS Shim, et al. 2005 Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia Am J Respir Crit Care Med 171 639 644 10.1164/rccm.200403-331OC 15640368 (Pubitemid 40365421)
12. PI Latsi RM du Bois AG Nicholson, et al. 2003 Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends Am J Respir Crit Care Med 168 531 537 10.1164/rccm.200210-1245OC 12791580 (Pubitemid 37088594)
13. • Zappala CJ, Latsi PI, Nicholson AG, et al.: Marginal decline in FVC is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2009 Oct 19 (Epub ahead of print). This article describes findings which suggest that subtle changes in forced vital capacity can predict prognosis and outcome in IPF.
14. JH Park DS Kim IN Park, et al. 2007 Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes Am J Respir Crit Care Med 175 705 711 10.1164/rccm.200607-912OC 17218621 This article discusses one of the few studies comparing prognosis of IPF and CTD-associated ILD (Pubitemid 46536486)
15. A Fischer JJ Swigris SD Groshong, et al. 2008 Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival Chest 134 601 605 10.1378/chest.08-0053 18403656
16. RM Silver AU Wells 2008 Histopathology and bronchoalveolar lavage Rheumatology (Oxford) 47 v62 v64 10.1093/rheumatology/ken272
17. M Suga K Iyonaga T Okamoto, et al. 2000 Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias Am J Respir Crit Care Med 162 1949 1956 1:STN:280:DC%2BD3M%2FkvF2hug%3D%3D 11069839
18. GN Andersen K Nilsson J Pourazar, et al. 2007 Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis Respir Med 101 2199 2206 10.1016/j.rmed.2007.04.019 17643278 (Pubitemid 47333670)
19. NK Harrison AD Cambrey AR Myers, et al. 1994 Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis Clin Sci (Colch) 86 141 148 1:STN:280:DyaK2c7pt1ejug%3D%3D
20. A Prasse DV Pechkovsky GB Toews, et al. 2007 CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis Arthritis Rheum 56 1685 1693 10.1002/art.22559 1:CAS:528: DC%2BD2sXmsFartb8%3D 17469163 (Pubitemid 46764100)
21. MB Bolster A Ludwicka SE Sutherland, et al. 1997 Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis Arthritis Rheum 40 743 751 10.1002/art.1780400422 1:STN:280:DyaK2s3ksVeisg%3D%3D 9125259 (Pubitemid 27157582)
22. KM Antoniou M Mamoulaki K Malagari, et al. 2007 Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease Clin Exp Rheumatol 25 23 28 1:STN:280:DC%2BD2s3htlOnug%3D%3D 17417986
23. R Vassallo E Matteson CF Thomas Jr 2002 Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition Chest 122 1093 1096 10.1378/chest.122.3.1093 12226061
24. G Raghu KK Brown U Costabel, et al. 2008 Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial Am J Respir Crit Care Med 178 948 955 10.1164/rccm.200709-1446OC 1:CAS:528:DC%2BD1cXhsVemsbzM 18669816
25. N Kohno Y Awaya T Oyama, et al. 1993 KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease Am Rev Respir Dis 148 637 642 1:STN:280:DyaK3sznvVWqtQ%3D%3D 8368634
26. Y Honda Y Kuroki E Matsuura, et al. 1995 Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids Am J Respir Crit Care Med 152 1860 1866 1:STN:280:DyaK28%2FpsVahuw%3D%3D 8520747
27. N Fertig RT Domsic T Rodriguez-Reyna, et al. 2009 Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis Arthritis Rheum 61 958 965 10.1002/art.24586 1:CAS:528:DC%2BD1MXhtVSntbbL 19565553 This article describes a new autoantibody associated with severe progressive lung fibrosis in SSc and compares its frequency with that of other ILD-associated circulating autoantibodies
28. A Fischer FJ Pfalzgraf CA Feghali-Bostwick, et al. 2006 Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis J Rheumatol 33 1600 1605 16783860
29. T Kakugawa S-I Yokota H Mukae, et al. 2008 High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis BMC Pulm Med 8 23 10.1186/1471-2466-8-23 18983650
30. Y Yang J Fujita S Bandoh, et al. 2002 Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia Clin Exp Immunol 128 169 174 10.1046/j.1365-2249.2002. 01811.x 1:CAS:528:DC%2BD38XksFSmtbo%3D 11982605 (Pubitemid 34451195)
31. CA Feghali-Bostwick CG Tsai VG Valentine, et al. 2007 Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis J Immunol 179 2592 2599 1:CAS:528:DC%2BD2sXosVyqtr8%3D 17675522 Research described in this manuscript demonstrates that, as with SSc, IPF has features of autoimmune diseases
32. J Fujita N Dobashi Y Ohtsuki, et al. 1999 Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders Lung 177 311 319 10.1007/PL00007649 1:STN:280:DyaK1Mzps1Ohtg%3D%3D 10467022 (Pubitemid 29420469)
33. FC Arnett M Cho S Chatterjee, et al. 2001 Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts Arthritis Rheum 44 1359 1362 10.1002/1529-0131(200106)44:6<1359::AID- ART228>3.0.CO;2-S 1:STN:280:DC%2BD3MzksVOnsA%3D%3D 11407695 (Pubitemid 32537534)
34. H Englert J Small-McMahon P Chambers, et al. 1999 Familial risk estimation in systemic sclerosis Aust N Z J Med 29 36 41 1:STN:280: DyaK1M3hs1yiug%3D%3D 10200811
35. C Feghali-Bostwick TA Medsger Jr TM Wright 2003 Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies Arthritis Rheum 48 1956 1963 10.1002/art.11173 12847690 This article describes the only study examining concordance for SSc and the presence of antinuclear antibodies in twins (Pubitemid 36828691)
36. X Zhou FK Tan M Xiong, et al. 2005 Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles Arthritis Rheum 52 3305 3314 10.1002/art.21355 1:CAS:528: DC%2BD2MXhtF2msrjK 16200604 (Pubitemid 41447114)
37. P Dieude M Guedj J Wipff, et al. 2009 STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis Arthritis Rheum 60 2472 2479 10.1002/art.24688 1:CAS:528:DC%2BD1MXhtV2hsLfK 19644887
38. WR Coward K Watts CA Feghali-Bostwick, et al. 2009 Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis Mol Cell Biol 29 4325 4339 10.1128/MCB.01776-08 1:CAS:528:DC%2BD1MXptFeht70%3D 19487460
39. W Glenisson V Castronovo D Waltregny 2007 Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation Biochim Biophys Acta 1773 1572 1582 10.1016/j.bbamcr.2007.05.016 1:CAS:528:DC%2BD2sXhtFehsrvJ 17610967 (Pubitemid 47498609)
40. Y Wang PS Fan B Kahaleh 2006 Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts Arthritis Rheum 54 2271 2279 10.1002/art.21948 1:CAS:528: DC%2BD28XnslKhu7s%3D 16802366 This is the first published report of altered methylation in SSc (Pubitemid 44051084)
41. YY Sanders A Pardo M Selman, et al. 2008 Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis Am J Respir Cell Mol Biol 39 610 618 10.1165/rcmb.2007-0322OC 1:CAS:528:DC%2BD1cXhtlGltrvL 18556592 This is the first published report of altered methylation in IPF
42. MY Armanios JJ Chen JD Cogan, et al. 2007 Telomerase mutations in families with idiopathic pulmonary fibrosis N Engl J Med 356 1317 1326 10.1056/NEJMoa066157 1:CAS:528:DC%2BD2sXjsFKhsL0%3D 17392301 (Pubitemid 46513297)
43. KD Tsakiri JT Cronkhite PJ Kuan, et al. 2007 Adult-onset pulmonary fibrosis caused by mutations in telomerase Proc Natl Acad Sci USA 104 7552 7557 10.1073/pnas.0701009104 1:CAS:528:DC%2BD2sXlslWqtL4%3D 17460043 (Pubitemid 47185944)
44. T Ohtsuka A Yamakage S Yamazaki 2002 The polymorphism of telomerase RNA component gene in patients with systemic sclerosis Br J Dermatol 147 250 254 10.1046/j.1365-2133.2002.04937.x 1:CAS:528:DC%2BD38XnsVSkurw%3D 12174094
45. Y Katayama K Kohriyama 2001 Telomerase activity in peripheral blood mononuclear cells of systemic connective tissue diseases J Rheumatol 28 288 291 1:CAS:528:DC%2BD3MXhs1Smu7c%3D 11246663
46. CP Denton PA Merkel DE Furst, et al. 2007 Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum 56 323 333 10.1002/art.22289 1:CAS:528:DC%2BD2sXhsFaisL8%3D 17195236 This study demonstrates that although TGF-β is considered a central mediator of fibrosis in SSc and related diseases, a TGF-β-blocking antibody failed to show efficacy in a clinical trial (Pubitemid 46106206)
47. C Aston J Jagirdar TC Lee, et al. 1995 Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 151 1597 1603 1:STN:280:DyaK2M3ltlGktw%3D%3D 7537587
48. E Hsu CA Feghali-Bostwick 2008 Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways Am J Pathol 172 1580 1590 10.2353/ajpath.2008.071021 1:CAS:528:DC%2BD1cXnslKjsro%3D 18467708 (Pubitemid 351793351)
49. JM Pilewski L Liu AC Henry, et al. 2005 Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition Am J Pathol 166 399 407 1:CAS:528:DC%2BD2MXitVGnurs%3D 15681824
50. H Yasuoka AT Larregina Y Yamaguchi CA Feghali-Bostwick 2008 Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins Open Rheumatol J 2 17 22 10.2174/ 1874312900802010017 1:CAS:528:DC%2BD1cXlslensrY%3D 19088866 This article describes the use of an ex vivo human skin organ culture model to assess the effect of fibrotic and antifibrotic molecules, minimize the use of animal models, and render findings more directly applicable to human disease